Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

Background: In Crohn’s disease and ulcerative colitis, the anti-α4β7 integrin antibody vedolizumab has demonstrated efficacy in phase III trials and has been successfully used under real-world conditions. Occasionally, it has also been used in other forms of inflammatory bowel disease (IBD) such as...

Full description

Bibliographic Details
Main Authors:	Laura Besendorf, Tanja M. Müller, Carol-Immanuel Geppert, Ines Schneider, Laura Mühl, Imke Atreya, Francesco Vitali, Raja Atreya, Markus F. Neurath, Sebastian Zundler
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-06-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848221098899

Similar Items

Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
by: Clarissa Allner, et al.
Published: (2020-04-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
by: Laura Mühl, et al.
Published: (2021-01-01)

The Force-Dependent Mechanism of an Integrin α4β7–MAdCAM-1 Interaction
by: Youmin Su, et al.
Published: (2023-11-01)

Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity.
by: Newham, P, et al.
Published: (1997)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
by: Timo Rath, et al.
Published: (2018-07-01)

Development of Mucosal PNAd<sup>+</sup> and MAdCAM-1<sup>+</sup> Venules during Disease Course in Ulcerative Colitis
by: Britt Roosenboom, et al.
Published: (2020-04-01)

Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance
by: Marine Fidelle, et al.
Published: (2023-12-01)

TNF-α induced endothelial MAdCAM-1 expression is regulated by exogenous, not endogenous nitric oxide
by: Alexander Jonathan S, et al.
Published: (2001-07-01)

Circulating MAdCAM-1 and ITGB7 in Patients with Plaque Psoriasis and Eruptive Lichen Planus—Preliminary Data
by: Anna Baran, et al.
Published: (2021-11-01)

Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kB.
by: Minagar Alireza, et al.
Published: (2002-04-01)

Force-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 Mediated by Integrin α<sub>4</sub>β<sub>7</sub>/MAdCAM-1 in Flow
by: Dongshan Sun, et al.
Published: (2023-03-01)

s MadCAM-1 as an immunological marker in the «gut liver axis» at patients with chronic hepatitis C and excess body weight
by: K. V. Zhdanov, et al.
Published: (2019-05-01)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
by: Aylin Lindemann, et al.
Published: (2023-06-01)

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
by: Masayuki Saruta, et al.
Published: (2020-01-01)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
by: Sebastian Zundler, et al.
Published: (2023-05-01)

Correction: A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3.
by: Géraldine Arrode-Brusés, et al.
Published: (2016-07-01)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
by: Timo Rath, et al.
Published: (2023-10-01)

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine
by: Karin Heidbreder, et al.
Published: (2023-01-01)

Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis
by: Francesco Vitali, et al.
Published: (2024-01-01)

Anti‐β7 integrin treatment impedes the recruitment on non‐classical monocytes to the gut and delays macrophage‐mediated intestinal wound healing
by: Katrin Sommer, et al.
Published: (2023-04-01)

Transfection of IL-10 expression vectors into endothelial cultures attenuates α4β7-dependent lymphocyte adhesion mediated by MAdCAM-1
by: Joh Takashi, et al.
Published: (2003-02-01)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
by: Imke Atreya, et al.
Published: (2022-11-01)

Differential Effects of the Absence of Nkx2-3 and MAdCAM-1 on the Distribution of Intestinal Type 3 Innate Lymphoid Cells and Postnatal SILT Formation in Mice
by: Dóra Vojkovics, et al.
Published: (2019-03-01)

MAdCAM-1 costimulation in the presence of retinoic acid and TGF-β promotes HIV infection and differentiation of CD4+ T cells into CCR5+ TRM-like cells.
by: Sinmanus Vimonpatranon, et al.
Published: (2023-03-01)

Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer
by: Sebastian Zundler, et al.
Published: (2016-02-01)

Cholinergic Anti-inflammatory Pathway Attenuates Acute Liver Failure Through Inhibiting MAdCAM1/α4β7-mediated Gut-derived Proinflammatory Lymphocytes AccumulationSummary
by: Shan Fu, et al.
Published: (2024-01-01)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
by: Laurent Peyrin‐Biroulet, et al.
Published: (2024-03-01)

Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells
by: Maximilian Wiendl, et al.
Published: (2024-02-01)

Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation
by: Anja Schulz-Kuhnt, et al.
Published: (2020-06-01)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
by: Renato Sablich, et al.
Published: (2023-02-01)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
by: Kothari M, et al.
Published: (2015-08-01)

Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time
by: Stefan Wirtz, et al.
Published: (2021-06-01)

Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases
by: Anja Schulz-Kuhnt, et al.
Published: (2021-03-01)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
by: Raja Atreya, et al.
Published: (2020-09-01)

Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis
by: Ingo Ganzleben, et al.
Published: (2020-10-01)

Role of the IL23/IL17 Pathway in Crohn’s Disease
by: Heike Schmitt, et al.
Published: (2021-03-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
by: Ayaka Kaneoka, et al.
Published: (2022-02-01)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
by: Gilroy L, et al.
Published: (2014-05-01)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
by: Maria Gonzalez-Vivo, et al.
Published: (2022-06-01)